26 min listen
Inside NK and Macrophage Cellular Immunotherapies with Shoreline Biosciences CSO Dr. Robert Hollingsworth
Inside NK and Macrophage Cellular Immunotherapies with Shoreline Biosciences CSO Dr. Robert Hollingsworth
ratings:
Length:
27 minutes
Released:
Dec 22, 2022
Format:
Podcast episode
Description
Shoreline Biosciences' Chief Scientific Officer Dr. Robert Hollingsworth shares his insight on intelligently designed allogeneic off-the-shelf, standardized, and targeted iPSC-derived natural killers (NK) and macrophage cellular immunotherapies. He explains the company's preclinical testing on a potential NK cell therapy for acute myeloid leukemia. We discuss how the field recognizes the importance of off-the-shelf NK cell therapy not only for cost reduction but also for improving safety measures. As such, Dr. Hollingsworth talks through why NK cells necessary to move immunotherapies forward.
Released:
Dec 22, 2022
Format:
Podcast episode
Titles in the series (75)
State-of-the-Art GMP Manufacturing RNA Cell Therapies with Cartesian's CEO by Cell & Gene: The Podcast